AGIO
Price
$37.71
Change
-$0.47 (-1.23%)
Updated
Aug 29 closing price
Capitalization
2.19B
61 days until earnings call
SYRE
Price
$16.49
Change
-$0.23 (-1.38%)
Updated
Aug 29 closing price
Capitalization
996.01M
68 days until earnings call
Interact to see
Advertisement

AGIO vs SYRE

Header iconAGIO vs SYRE Comparison
Open Charts AGIO vs SYREBanner chart's image
Agios Pharmaceuticals
Price$37.71
Change-$0.47 (-1.23%)
Volume$502.79K
Capitalization2.19B
Spyre Therapeutics
Price$16.49
Change-$0.23 (-1.38%)
Volume$351.93K
Capitalization996.01M
AGIO vs SYRE Comparison Chart in %
Loading...
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AGIO vs. SYRE commentary
Aug 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGIO is a Buy and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 30, 2025
Stock price -- (AGIO: $37.71 vs. SYRE: $16.49)
Brand notoriety: AGIO and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGIO: 61% vs. SYRE: 64%
Market capitalization -- AGIO: $2.19B vs. SYRE: $996.01M
AGIO [@Biotechnology] is valued at $2.19B. SYRE’s [@Biotechnology] market capitalization is $996.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGIO’s FA Score shows that 1 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • AGIO’s FA Score: 1 green, 4 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, AGIO is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGIO’s TA Score shows that 7 TA indicator(s) are bullish while SYRE’s TA Score has 6 bullish TA indicator(s).

  • AGIO’s TA Score: 7 bullish, 4 bearish.
  • SYRE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, both AGIO and SYRE are a good buy in the short-term.

Price Growth

AGIO (@Biotechnology) experienced а -2.81% price change this week, while SYRE (@Biotechnology) price change was -5.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.70%. For the same industry, the average monthly price growth was +20.57%, and the average quarterly price growth was +29.45%.

Reported Earning Dates

AGIO is expected to report earnings on Oct 30, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (-0.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AGIO($2.19B) has a higher market cap than SYRE($996M). AGIO has higher P/E ratio than SYRE: AGIO (3.34) vs SYRE (1.72). AGIO YTD gains are higher at: 14.760 vs. SYRE (-29.167). SYRE has higher annual earnings (EBITDA): -222.15M vs. AGIO (-456.28M). AGIO has more cash in the bank: 939M vs. SYRE (527M). SYRE has less debt than AGIO: SYRE (0) vs AGIO (48.8M). AGIO has higher revenues than SYRE: AGIO (40.9M) vs SYRE (0).
AGIOSYREAGIO / SYRE
Capitalization2.19B996M220%
EBITDA-456.28M-222.15M205%
Gain YTD14.760-29.167-51%
P/E Ratio3.341.72195%
Revenue40.9M0-
Total Cash939M527M178%
Total Debt48.8M0-
FUNDAMENTALS RATINGS
AGIO vs SYRE: Fundamental Ratings
AGIO
SYRE
OUTLOOK RATING
1..100
216
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1797
PRICE GROWTH RATING
1..100
5362
P/E GROWTH RATING
1..100
6883
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AGIO's Valuation (39) in the Biotechnology industry is somewhat better than the same rating for SYRE (72) in the Pharmaceuticals Major industry. This means that AGIO’s stock grew somewhat faster than SYRE’s over the last 12 months.

AGIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that AGIO’s stock grew similarly to SYRE’s over the last 12 months.

AGIO's SMR Rating (17) in the Biotechnology industry is significantly better than the same rating for SYRE (97) in the Pharmaceuticals Major industry. This means that AGIO’s stock grew significantly faster than SYRE’s over the last 12 months.

AGIO's Price Growth Rating (53) in the Biotechnology industry is in the same range as SYRE (62) in the Pharmaceuticals Major industry. This means that AGIO’s stock grew similarly to SYRE’s over the last 12 months.

AGIO's P/E Growth Rating (68) in the Biotechnology industry is in the same range as SYRE (83) in the Pharmaceuticals Major industry. This means that AGIO’s stock grew similarly to SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGIOSYRE
RSI
ODDS (%)
Bearish Trend 6 days ago
78%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
UISCX14.40N/A
N/A
Victory Small Cap Stock Institutional
SBFIX22.32N/A
N/A
Federated Hermes Global Allocation IS
ERASX41.58N/A
N/A
Eaton Vance Atlanta Capital SMID-Cap R6
CAPOX10.73N/A
N/A
Absolute Capital Opportunities Instl
TQCIX19.90N/A
N/A
Touchstone Dividend Equity Institutional